BioNTech
An der Goldgrube 12
Mainz
D-55131
Germany
280 articles with BioNTech
-
Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.
-
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
6/10/2021
Pfizer Inc. and BioNTech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic.
-
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
-
Importantly, the researchers recovered virus that they were able to culture, indicating a high risk for transmissibility.
-
A flurry of COVID-19 research news came out today. Here’s a look.
-
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
5/28/2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age.
-
The FDA has a massive backlog of site inspections due to the pandemic. To address the problem, the agency made its Resiliency Roadmap outlining its priorities.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
-
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults
5/24/2021
Pfizer Inc. announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration under an Emergency Use Authorization.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Researchers at John Hopkins made their preliminary conclusions that the vaccines produced by Pfizer-BioNTech and Moderna did not cause the hearing loss.
-
BioSpace Movers & Shakers, May 21
5/21/2021
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG
5/21/2021
BioNTech is committed to contributing to the UN Sustainable Development Goals (SDGs), particularly the promotion of good health and well-being for all people of all ages
-
Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine
5/20/2021
Pfizer Inc. and BioNTech SE announced that the BioNTech Europe GmbH has entered into an agreement with Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ COVID-19 vaccine, with an option for an additional 30 million doses.
-
Health Canada authorizes more flexible storage conditions for Pfizer-BioNTech COVID-19 vaccine
5/19/2021
Health Canada authorized a submission from Pfizer-BioNTech to allow its COVID-19 vaccine to be stored at regular refrigerated temperatures at the point of use for up to one month.
-
X-Vax Technology is preparing to submit an IND application to the U.S. FDA for its experimental vaccine against Herpes simplex virus 1 and 2 (HSV-1 and -2).
-
Thermo Fisher Plans Cell Therapy Manufacturing Site in Bay Area; Pfizer Expands Irish Plant
5/19/2021
Thermo Fisher and the University of California partnered with the development and manufacturing of cell-based therapies with the construction of its 44,000 sq. ft. manufacturing facility. -
FDA says it is possible booster shots would be necessary for fully vaccinated individuals within a year even though vaccines are highly effective at COVID-19 prevention.